SHIELD Lab
@bgauthierlab.bsky.social
Strategic Healing and Immuno-Endocrine Division led by BGauthier at @cabimer @FProgresoysalud. With @BreakthroughT1D, @diabetes_CERO, @ciberdem
Pinned
SHIELD Lab
@bgauthierlab.bsky.social
· Nov 14
The lab’s official account is here! Welcome to @bgauthierlab.bsky.social (Strategic Healing and Immuno-Endocrine Division/SHIELD LAB). Follow us for updates on our latest research, publications, and news. Stay connected for exciting discoveries ahead 💯💪⬇️⬇️
No te pierdas esta noche en "Los Reporteros" un reportaje exclusivo para entender, conocer y ver cómo luchar contra la #DiabetesTipo1. Conduce la maravillosa periodista
@mabelmata1 y participa nuestro querido @sevillegauthier
quien hablará sobre su innovador trabajo en este campo.
@mabelmata1 y participa nuestro querido @sevillegauthier
quien hablará sobre su innovador trabajo en este campo.
February 8, 2025 at 3:49 PM
No te pierdas esta noche en "Los Reporteros" un reportaje exclusivo para entender, conocer y ver cómo luchar contra la #DiabetesTipo1. Conduce la maravillosa periodista
@mabelmata1 y participa nuestro querido @sevillegauthier
quien hablará sobre su innovador trabajo en este campo.
@mabelmata1 y participa nuestro querido @sevillegauthier
quien hablará sobre su innovador trabajo en este campo.
Do not miss this excellent review on the roles of Bcl-2 & Bcl-xL beyond apoptosis, detailing their impact on β-cell survival, calcium homeostasis, mitochondrial function, and diabetes progression. It also discusses therapeutic strategies targeting these pathways. A must-read! 👏🔬
🚨 New publication alert!
We're excited to share our latest paper in Biomedicines!
"Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function"
🔗 Read it here: mdpi.com/2227-9059/13...
#OpenAccess #Diabetes #Research
We're excited to share our latest paper in Biomedicines!
"Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function"
🔗 Read it here: mdpi.com/2227-9059/13...
#OpenAccess #Diabetes #Research
Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function
Diabetes is a chronic metabolic disorder whose prevalence increases every year, affecting more than 530 million adults worldwide. Type 1 (T1D) and type 2 diabetes (T2D), the most common forms of diabe...
mdpi.com
January 30, 2025 at 4:17 AM
Do not miss this excellent review on the roles of Bcl-2 & Bcl-xL beyond apoptosis, detailing their impact on β-cell survival, calcium homeostasis, mitochondrial function, and diabetes progression. It also discusses therapeutic strategies targeting these pathways. A must-read! 👏🔬
Reposted by SHIELD Lab
Excited to share our latest paper on LRH‐1/NR5A2: targeting mitochondrial dynamics to reprogram macrophages and dendritic cells in T1D into an immune-tolerant phenotype! Thanks to the amazing team&collaborators 🙌 #T1D #Mitochondria #NuclearReceptors #Immunometabolism
doi.org/10.1002/ctm2...
doi.org/10.1002/ctm2...
LRH‐1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype
LRH-1/NR5A2 activation in inflammatory cells of individuals with type 1 diabetes (T1D) reduces pro-inflammatory cell surface markers and cytokine release. LRH-1/NR5A2 promotes a mitohormesis-induce...
doi.org
December 20, 2024 at 6:05 PM
Excited to share our latest paper on LRH‐1/NR5A2: targeting mitochondrial dynamics to reprogram macrophages and dendritic cells in T1D into an immune-tolerant phenotype! Thanks to the amazing team&collaborators 🙌 #T1D #Mitochondria #NuclearReceptors #Immunometabolism
doi.org/10.1002/ctm2...
doi.org/10.1002/ctm2...
Thrilled to begin a new chapter with @diabetes_CERO! Their generous funding helps us secure the talent needed to develop 2nd-gen LRH-1/NR5A2 agonists for #T1D treatments. Thanks for your continued support in the fight against T1D!@cabimer @AndaluciaJunta @BreakthroughT1D lc.cx/xB2awa
Investigadores evalúan el potencial antidiabético de moléculas de segunda generación
- El grupo de científicos de la Fundación Progreso y Salud, liderado por Benoit Gauthier, ha recibido financiación de la Fundación DiabetesCERO para impulsar este proyecto
lc.cx
January 28, 2025 at 8:11 AM
Thrilled to begin a new chapter with @diabetes_CERO! Their generous funding helps us secure the talent needed to develop 2nd-gen LRH-1/NR5A2 agonists for #T1D treatments. Thanks for your continued support in the fight against T1D!@cabimer @AndaluciaJunta @BreakthroughT1D lc.cx/xB2awa
Excited to share our latest paper on LRH‐1/NR5A2: targeting mitochondrial dynamics to reprogram macrophages and dendritic cells in T1D into an immune-tolerant phenotype! Thanks to the amazing team&collaborators 🙌 #T1D #Mitochondria #NuclearReceptors #Immunometabolism
doi.org/10.1002/ctm2...
doi.org/10.1002/ctm2...
LRH‐1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype
LRH-1/NR5A2 activation in inflammatory cells of individuals with type 1 diabetes (T1D) reduces pro-inflammatory cell surface markers and cytokine release. LRH-1/NR5A2 promotes a mitohormesis-induce...
doi.org
December 20, 2024 at 6:05 PM
Excited to share our latest paper on LRH‐1/NR5A2: targeting mitochondrial dynamics to reprogram macrophages and dendritic cells in T1D into an immune-tolerant phenotype! Thanks to the amazing team&collaborators 🙌 #T1D #Mitochondria #NuclearReceptors #Immunometabolism
doi.org/10.1002/ctm2...
doi.org/10.1002/ctm2...
🚨 New Research 🚨
Our latest study in Clin. Transl. Med. shows LRH-1/NR5A2 activation fosters immune tolerance in T1D by reducing inflammation, promoting tolerogenic dendritic cells, and expanding regulatory T-cells.
A step forward in T1D research. 🙌
dx.doi.org/10.1002/ctm2...
Our latest study in Clin. Transl. Med. shows LRH-1/NR5A2 activation fosters immune tolerance in T1D by reducing inflammation, promoting tolerogenic dendritic cells, and expanding regulatory T-cells.
A step forward in T1D research. 🙌
dx.doi.org/10.1002/ctm2...
LRH‐1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype
LRH-1/NR5A2 activation in inflammatory cells of individuals with type 1 diabetes (T1D) reduces pro-inflammatory cell surface markers and cytokine release. LRH-1/NR5A2 promotes a mitohormesis-induce...
dx.doi.org
December 20, 2024 at 10:43 AM
🚨 New Research 🚨
Our latest study in Clin. Transl. Med. shows LRH-1/NR5A2 activation fosters immune tolerance in T1D by reducing inflammation, promoting tolerogenic dendritic cells, and expanding regulatory T-cells.
A step forward in T1D research. 🙌
dx.doi.org/10.1002/ctm2...
Our latest study in Clin. Transl. Med. shows LRH-1/NR5A2 activation fosters immune tolerance in T1D by reducing inflammation, promoting tolerogenic dendritic cells, and expanding regulatory T-cells.
A step forward in T1D research. 🙌
dx.doi.org/10.1002/ctm2...
Reposted by SHIELD Lab
We are recruiting a postdoctoral research associate! Have a look at the flyer and/or the links below and get in touch if you have any questions! And please, share widely!!
www.imperial.ac.uk/jobs/search-...
www.imperial.ac.uk/jobs/search-...
November 27, 2024 at 5:50 PM
We are recruiting a postdoctoral research associate! Have a look at the flyer and/or the links below and get in touch if you have any questions! And please, share widely!!
www.imperial.ac.uk/jobs/search-...
www.imperial.ac.uk/jobs/search-...
November 16, 2024 at 10:59 AM
A review we published on the idea that #T1D and autoimmune diseases should be considered unresolved wound-healing and that the optimal treatment should reeducate, NOT suppress, the immune system to allow regeneration. Food for thought
www.metabolismjournal.com/article/S002...
www.metabolismjournal.com/article/S002...
November 14, 2024 at 7:46 PM
A review we published on the idea that #T1D and autoimmune diseases should be considered unresolved wound-healing and that the optimal treatment should reeducate, NOT suppress, the immune system to allow regeneration. Food for thought
www.metabolismjournal.com/article/S002...
www.metabolismjournal.com/article/S002...
The lab’s official account is here! Welcome to @bgauthierlab.bsky.social (Strategic Healing and Immuno-Endocrine Division/SHIELD LAB). Follow us for updates on our latest research, publications, and news. Stay connected for exciting discoveries ahead 💯💪⬇️⬇️
November 14, 2024 at 5:44 PM
The lab’s official account is here! Welcome to @bgauthierlab.bsky.social (Strategic Healing and Immuno-Endocrine Division/SHIELD LAB). Follow us for updates on our latest research, publications, and news. Stay connected for exciting discoveries ahead 💯💪⬇️⬇️